Pablo Zwanek

“Look, two more questions regarding Carlsberg. Can you give us a sense, you know, what's the upside there in terms of revenues? I don't know who was producing or distributing Carlsberg before, you know, what were their peak sales?”

“And I know this is just speculation, but given, you know, the backdrop on private credit and, you know, everything that's been going on, not your case, of course, you perform stellarly in that context compared to the rest of the industry. wouldn't that make you think that the SEC would take longer because of that?”

“The first question, Mike, and I think we've talked about this before, you know, if you can give more color about your route to market in Europe, or is it pretty much an FOB model in which you sell to distributors and they take care of the distribution and selling to pharmacies, or color in terms of how your company's…”

“Everyone, look, just to follow up on the medical side of things regarding the impact on veterans, we are now in the middle of June. Can you give some color in terms of how are, you know, veteran users of medical cannabis reacting?”

“Look, I obviously have a lot of questions that I want to ask here, given all the very positive news and, of course, positive performance. Let me start with the CMS program.”